Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 11, 2011, Pages 2525-2538

  Vaidyanath, Arun ^a   Hashizume, Toshihiro ^a   Nagaoka, Tadahiro ^a,b   Takeyasu, Nao ^a   Satoh, Hitomi ^a   Chen, Ling ^a   Wang, Jiyou ^a   Kasai, Tomonari ^a   Kudoh, Takayuki ^a   Satoh, Ayano ^a   Fu, Li ^c   Seno, Masaharu ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Bionanocapsule; EC 1 peptide; ErbB2; Internalization; Multivalent display

Indexed keywords

CAVEOLIN 1; CHOLESTEROL; CLATHRIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; LIGAND; PEPTIDE;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PROTEIN BINDING; PROTEIN TRANSPORT; TUMOR CELL LINE;

BREAST NEOPLASMS; CAVEOLIN 1; CELL LINE, TUMOR; CHOLESTEROL; CLATHRIN; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; LIGANDS; OVARIAN NEOPLASMS; PEPTIDES; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTOR, ERBB-2;

EID: 79953793965     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01277.x     Document Type: Article

References (47)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nature Rev Mol Cell Biol. 2001; 2: 127-37.
2. Olayioye MA, Neve, RM, Lane HA, et al The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 9: 3159-67.
3. Klapper LN, Waterman H, Sela M, et al Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 2000; 60: 3384-8.
4. Slamon DJ, Clark GM, Wong SG, et al Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-82.
5. Hynes, NE, Stern DF. The biology of ErbB2/neu/HER-2 and its role in Cancer. Biochem Biophys Acta. 1994; 1198: 164-84.
6. De Placido S, Carlamangno C, De Laurentiis M, et al C-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat. 1998; 52: 55-64.
7. Pinkas-Kramarski R, Soussan L, Waterman H, et al Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996; 15: 2452-67.
8. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-75.
9. Salomon DS, Brandt R, Ciardiello F, et al Epidermal growth factor-related peptide and their receptors in human malignancies. Crit Rev Oncol Ematol. 1995; 19: 183-232.
10. Slamon DJ, Godolphin W, Jones LA, et al Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-12.
11. Zhang X, Silva E, Gershenson D, et al Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene 1989; 4: 985-9.
12. Austin CD, De Maziere AM, Pisacane PI, et al Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004; 15: 5268-82.
13. Hommelgaard AM, Lerdrup M, van Deurs B. Association with membrane protrusions makes ErbB2 and internalization-resistant receptor. Mol Biol Cell. 2004; 15: 1557-67.
14. Lerdrup M, Brunn S, Grandal MV, et al Endocytic downregulation of ErbB2 is stimulated by cleavage of its C-terminus. Mol Biol Cell. 2007; 18: 3656-66.
15. Lerdrup M, Hommelgaard AM, Grandal MV, et al Geldanamycin stimulates internalization of ErbB2 in a proteosome-dependent pathway. J Cell Sci. 2006; 119: 85-95.
16. Hudziak RM, Lewis GD, Winget M, et al P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 1989; 9: 1165-72.
17. Lewis GD, Lofgren JA, McMurtey AE, et al Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res. 1996; 56: 1457-65.
18. Cuello M, Ettenberg SA, Clark AS, et al Downregulation of the erbB2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor related apoptosis inducing ligand mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB2. Cancer Res. 2001; 61: 4892-900.
19. Baselga J, Albanell J, Molina MA, et al Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001; 28: 4-11.
20. Urbanelli L, Ronchini C, Fontana L, et al Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage. J Mol Biol. 2001; 313: 965-76.
21. Karasseva NG, Glinsky VV, Chen NX, et al Identification and characterization of peptides that bind human ErbB2 selected from a bacteriophage display library. J Protein Chem. 2002; 21: 287-96.
22. Houimel M, Schneider P, Terskikh A, et al Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. Int J Cancer. 2001; 92: 748-55.
23. Pero SC, Shukla GS, Armstrong AL, et al Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer. 2004; 111: 951-60.
24. Hashizume T, Fukuda T, Nagaoka T, et al Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. Cell Biol Int. 2008; 32: 814-26.
25. Tsutsui Y, Tomizawa K, Nagita M, et al Development of bionanocapsules targeting brain tumors. J Control Release 2007; 122: 159-64.
26. Tada H, Kurokawa T, Seita T, et al Expression and characterization of a chimeric bispecific antibody against fibrin and against urokinase-type plasminogen activator. J Biotech. 1994; 33: 157-74.
27. Seno M, Futami J, Kosaka M, et al Nucleotide sequence encoding human pancreatic ribonuclease. Biochim Biophys Acta. 1994; 1218: 466-8.
28. Nagaoka T, Fukuda T, Hashizume T, et al A betacellulin mutant promotes differentiation of pancreatic acinar AR42J cells into insulin-producing cells with low affinity of binding to ErbB1. J Mol Biol. 2008; 380: 83-94.
29. Yamada T, Iwasaki Y, Tada H, et al Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. 2003; 21: 885-90.
30. Dini M, Jafari K, Faiferman I. Cell-mediated cytotoxicity in pre invasive and invasive squamous cell carcinoma of the cervix. Obstet Gynecol. 1980; 55: 728-31.
31. Hughes DPM, Thomas, DG, Giordano TJ, et al Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004; 64: 2047-53.
32. Friedman LM, Rinon A, Schechter B, et al Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci. 2005; 102: 1915-20.
33. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell. Biol. 2007; 8: 603-12.
34. Kirkham M, Parton RG. Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta. 2005; 1745: 272-86.
35. Barr DJ, Ostermeyer-Fay AG, Matundan RA, et al Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells. J Cell Sci. 2008; 121: 3155-66.
36. Sönnichsen B, De Renzis S, Neilsen E, et al Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab 11. J Cell Biol. 2000; 149: 901-14.
37. Falcone S, Cocucci E, Podini P, et al Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events. J Cell Sci. 2006; 119: 4758-69.
38. Sabharanjhak S, Sharma P, Parton RG, et al GPI-anchored proteins are delivered to recycling endosomems via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev Cell. 2002; 2: 411-23.
39. Chadda R, Howes MT, Plowman SJ, et al Cholesterol-sensitive Cdc42 activation regulates actin polymerization for endocytosis via the GEEC pathway. Traffic. 2007; 8: 702-17.
40. Brown FD, Rozelle AL, Yin HL, et al Phosphatidylinositol 4, 5-bisphosphate and Arf6-regulated membrane traffic. J Cell Biol. 2001; 154: 1007-18.
41. Mu F-T, Callaghan JM, Steele-Mortimer O, et al EEA1, an early endosome-associated protein. EEA 1 is a conserved alpha-helical peripheral membrane protein flanked by systeine "fingers" and contains a calmodulin-binding IQ motif. J Biol Chem. 1995; 270: 13503-11.
42. Mills I, Jones A, Clague M. Involvement of the endosomal autoantigen EEA1 in homotypic fusion of early endosomes. Curr Biol. 1998; 8: 881-4.
43. Sahay G, Alakhova YD, Kabanov VA. Endocytosis of nanomedicines. J. Con. Rel. 2010; 145: 182-95.
44. Lu Y, Low PS. Folate mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002; 54: 675-93.
45. Yu D, Fukuda T, Kuroda S, et al Engineered bio-nanocapsules, the selective vector for drug delivery system. IUBMB Life. 2006; 58: 1-6.
46. Tuoya, Hirayama K, Nagaoka T, et al Identification of cell surface marker candidates on SV-T2 cells using DNA microarray on DLC-coated glass. Biochem Biophys Res Commun. 2005; 334: 263-8.
47. Samah AS, Yuh Sugii, Tuoya, et al Identification of TM9SF2 as a candidate of the cell surface marker common to breast carcinoma cells. Clin Oncol Cancer Res. 2009; 6: 1-9.